Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Targeting the Host for New Therapeutic Perspectives in Hepatitis D.

Turon-Lagot V, Saviano A, Schuster C, Baumert TF, Verrier ER.

J Clin Med. 2020 Jan 14;9(1). pii: E222. doi: 10.3390/jcm9010222. Review.

2.

Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.

Wang YX, Niklasch M, Liu T, Wang Y, Shi B, Yuan W, Baumert TF, Yuan Z, Tong S, Nassal M, Wen YM.

J Hepatol. 2019 Dec 18. pii: S0168-8278(19)30722-6. doi: 10.1016/j.jhep.2019.12.009. [Epub ahead of print]

PMID:
31863794
3.

Follicular T helper cells shape the HCV-specific CD4+ T cell repertoire after virus elimination.

Smits M, Zoldan K, Ishaque N, Gu Z, Jechow K, Wieland D, Conrad C, Eils R, Fauvelle C, Baumert TF, Emmerich F, Bengsch B, Neumann-Haefelin C, Hofmann M, Thimme R, Boettler T.

J Clin Invest. 2020 Jan 21. pii: 129642. doi: 10.1172/JCI129642. [Epub ahead of print]

4.

Letter to the Editor: Abdominal Surgery in Idiopathic Noncirrhotic Portal Hypertension: Is Preemptive TIPS Reducing Postoperative Complications?

Felli E, Saviano A, Tripon S, Baumert TF, Pessaux P.

Hepatology. 2019 Oct 9. doi: 10.1002/hep.30985. [Epub ahead of print]

PMID:
31596950
5.

Hepatitis D Virus Infection Revisited.

Verrier ER, Majzoub K, Baumert TF.

Gastroenterology. 2019 Nov;157(5):1431-1432. doi: 10.1053/j.gastro.2019.09.029. Epub 2019 Oct 3. No abstract available.

PMID:
31586567
6.

Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis.

Virzì A, Roca Suarez AA, Baumert TF, Lupberger J.

Cold Spring Harb Perspect Med. 2020 Jan 2;10(1). pii: a037366. doi: 10.1101/cshperspect.a037366. Review.

PMID:
31501266
7.

Interleukin-32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance.

Dali-Youcef N, Vix M, Costantino F, El-Saghire H, Lhermitte B, Callari C, D'Agostino J, Perretta S, Paveliu S, Gualtierotti M, Dumeny E, Oudot MA, Jaulin A, Dembélé D, Zeisel MB, Tomasetto C, Baumert TF, Doffoël M.

Hepatol Commun. 2019 Jul 19;3(9):1205-1220. doi: 10.1002/hep4.1396. eCollection 2019 Sep.

8.

Radiomics in hepatocellular carcinoma: a quantitative review.

Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, Felli E, Saviano A, Agnus V, Savadjiev P, Baumert TF, Pessaux P, Marescaux J, Gallix B.

Hepatol Int. 2019 Sep;13(5):546-559. doi: 10.1007/s12072-019-09973-0. Epub 2019 Aug 31.

PMID:
31473947
9.

A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.

Johnson J, Freedman H, Logan M, Wong JAJ, Hockman D, Chen C, He J, Beard MR, Eyre NS, Baumert TF, Tyrrell DL, Law JLM, Houghton M.

J Virol. 2019 Oct 29;93(22). pii: e00810-19. doi: 10.1128/JVI.00810-19. Print 2019 Nov 15.

10.

The Innate Antiviral Response in Animals: An Evolutionary Perspective from Flagellates to Humans.

Majzoub K, Wrensch F, Baumert TF.

Viruses. 2019 Aug 16;11(8). pii: E758. doi: 10.3390/v11080758. Review.

11.

Uncovering the mechanism of action of aspirin in HCC chemoprevention.

Roehlen N, Baumert TF.

EBioMedicine. 2019 Aug;46:21-22. doi: 10.1016/j.ebiom.2019.07.047. Epub 2019 Aug 6. No abstract available.

12.

A human liver cell atlas reveals heterogeneity and epithelial progenitors.

Aizarani N, Saviano A, Sagar, Mailly L, Durand S, Herman JS, Pessaux P, Baumert TF, Grün D.

Nature. 2019 Aug;572(7768):199-204. doi: 10.1038/s41586-019-1373-2. Epub 2019 Jul 10.

13.

Hepatitis B Virus-Hepatocyte Interactions and Innate Immune Responses: Experimental Models and Molecular Mechanisms.

Thomas E, Baumert TF.

Semin Liver Dis. 2019 Jul;39(3):301-314. doi: 10.1055/s-0039-1685518. Epub 2019 Jul 2.

PMID:
31266064
14.

Mortality from liver cirrhosis and HCC in the DAA era: success in viral control is darkened by raise of metabolic disease.

Saviano A, Baumert TF.

Hepatobiliary Surg Nutr. 2019 Jun;8(3):307-310. doi: 10.21037/hbsn.2019.01.21. No abstract available.

15.

Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C.

Olbrich A, Wardemann H, Böhm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J.

J Infect Dis. 2019 Aug 30;220(7):1209-1218. doi: 10.1093/infdis/jiz274.

PMID:
31165162
16.

Ultrasound-Guided Approaches to Improve Orthotopic Mouse Xenograft Models for Hepatocellular Carcinoma.

Bou About G, Thiebault E, Wattenhofer-Donzé M, Jacobs H, Guimond A, Sorg T, Robinet E, Baumert TF, Monassier L, Herault Y.

Curr Protoc Mouse Biol. 2019 Jun;9(2):e62. doi: 10.1002/cpmo.62. Epub 2019 May 30.

PMID:
31145554
17.

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.

Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH.

PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May.

18.

Addressing the Challenges of Hepatitis C Cure and Persistent Risk of Hepatocellular Carcinoma.

Baumert TF, Hoshida Y.

Viruses. 2019 May 15;11(5). pii: E441. doi: 10.3390/v11050441.

19.

Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity.

Herzog K, Bandiera S, Pernot S, Fauvelle C, Jühling F, Weiss A, Bull A, Durand SC, Chane-Woon-Ming B, Pfeffer S, Mercey M, Lerat H, Meunier JC, Raffelsberger W, Brino L, Baumert TF, Zeisel MB.

Gut. 2020 Feb;69(2):380-392. doi: 10.1136/gutjnl-2018-317423. Epub 2019 May 10.

PMID:
31076402
20.

Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection.

Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF.

Hepatology. 2019 Nov;70(5):1506-1520. doi: 10.1002/hep.30699. Epub 2019 Jun 21.

PMID:
31062385
21.

Learning from a clinical cohort for HCV vaccine development.

Wrensch F, Keck ZY, Foung SKH, Baumert TF.

J Hepatol. 2019 Jul;71(1):9-11. doi: 10.1016/j.jhep.2019.03.030. Epub 2019 Apr 13. No abstract available.

PMID:
30992137
22.

Reply.

Verrier ER, Schuster C, Baumert TF.

Hepatology. 2019 Aug;70(2):766. doi: 10.1002/hep.30663. No abstract available.

PMID:
30991445
23.

Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development.

Lupberger J, Croonenborghs T, Roca Suarez AA, Van Renne N, Jühling F, Oudot MA, Virzì A, Bandiera S, Jamey C, Meszaros G, Brumaru D, Mukherji A, Durand SC, Heydmann L, Verrier ER, El Saghire H, Hamdane N, Bartenschlager R, Fereshetian S, Ramberger E, Sinha R, Nabian M, Everaert C, Jovanovic M, Mertins P, Carr SA, Chayama K, Dali-Youcef N, Ricci R, Bardeesy NM, Fujiwara N, Gevaert O, Zeisel MB, Hoshida Y, Pochet N, Baumert TF.

Gastroenterology. 2019 Aug;157(2):537-551.e9. doi: 10.1053/j.gastro.2019.04.003. Epub 2019 Apr 9.

PMID:
30978357
24.

The circadian clock and liver function in health and disease.

Mukherji A, Bailey SM, Staels B, Baumert TF.

J Hepatol. 2019 Jul;71(1):200-211. doi: 10.1016/j.jhep.2019.03.020. Epub 2019 Mar 28. Review.

PMID:
30930223
25.

Oxidative Stress Triggers Selective tRNA Retrograde Transport in Human Cells during the Integrated Stress Response.

Schwenzer H, Jühling F, Chu A, Pallett LJ, Baumert TF, Maini M, Fassati A.

Cell Rep. 2019 Mar 19;26(12):3416-3428.e5. doi: 10.1016/j.celrep.2019.02.077.

26.

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.

Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF.

Gastroenterology. 2019 Jun;156(8):2313-2329.e7. doi: 10.1053/j.gastro.2019.02.038. Epub 2019 Mar 2.

27.

Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.

Verrier ER, Weiss A, Bach C, Heydmann L, Turon-Lagot V, Kopp A, El Saghire H, Crouchet E, Pessaux P, Garcia T, Pale P, Zeisel MB, Sureau C, Schuster C, Brino L, Baumert TF.

Gut. 2020 Jan;69(1):158-167. doi: 10.1136/gutjnl-2018-317065. Epub 2019 Mar 4.

28.

The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication.

Zhuang X, Magri A, Hill M, Lai AG, Kumar A, Rambhatla SB, Donald CL, Lopez-Clavijo AF, Rudge S, Pinnick K, Chang WH, Wing PAC, Brown R, Qin X, Simmonds P, Baumert TF, Ray D, Loudon A, Balfe P, Wakelam M, Butterworth S, Kohl A, Jopling CL, Zitzmann N, McKeating JA.

Nat Commun. 2019 Jan 22;10(1):377. doi: 10.1038/s41467-019-08299-7.

29.

An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion.

Li C, Wang Y, Liu T, Niklasch M, Qiao K, Durand S, Chen L, Liang M, Baumert TF, Tong S, Nassal M, Wen YM, Wang YX.

Antiviral Res. 2019 Feb;162:118-129. doi: 10.1016/j.antiviral.2018.12.019. Epub 2018 Dec 30.

30.

In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.

Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF.

Antiviral Res. 2019 Feb;162:136-141. doi: 10.1016/j.antiviral.2018.12.018. Epub 2018 Dec 30.

31.

Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.

Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM.

Gut. 2019 May;68(5):893-904. doi: 10.1136/gutjnl-2018-316644. Epub 2018 Dec 22.

PMID:
30580250
32.

Editorial: Current Progress and Challenges in the Development of a B Cell Based Hepatitis C Virus Vaccine.

Foung SKH, Baumert TF.

Front Immunol. 2018 Nov 9;9:2577. doi: 10.3389/fimmu.2018.02577. eCollection 2018. No abstract available.

33.

Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis.

Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC.

J Gastrointest Surg. 2019 Jan;23(1):101-111. doi: 10.1007/s11605-018-4004-6. Epub 2018 Oct 26.

34.

Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Baumert TF, Berg T, Lim JK, Nelson DR.

Gastroenterology. 2019 Jan;156(2):431-445. doi: 10.1053/j.gastro.2018.10.024. Epub 2018 Oct 17. Review.

35.

Tight junction proteins in gastrointestinal and liver disease.

Zeisel MB, Dhawan P, Baumert TF.

Gut. 2018 Oct 8. pii: gutjnl-2018-316906. doi: 10.1136/gutjnl-2018-316906. [Epub ahead of print] Review.

36.

Oncogenic Signaling Induced by HCV Infection.

Virzì A, Roca Suarez AA, Baumert TF, Lupberger J.

Viruses. 2018 Oct 2;10(10). pii: E538. doi: 10.3390/v10100538. Review.

37.

Hepatitis B Virus Core Variants, Liver Fibrosis, and Hepatocellular Carcinoma.

Ligat G, Schuster C, Baumert TF.

Hepatology. 2019 Jan;69(1):5-8. doi: 10.1002/hep.30231. No abstract available.

38.

The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses.

Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C, Baumert TF.

Cell Mol Life Sci. 2018 Nov;75(21):3895-3905. doi: 10.1007/s00018-018-2892-y. Epub 2018 Aug 10. Review.

PMID:
30097692
39.

Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.

Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M.

J Virol. 2018 Sep 26;92(20). pii: e00939-18. doi: 10.1128/JVI.00939-18. Print 2018 Oct 15.

40.

Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.

Wrensch F, Crouchet E, Ligat G, Zeisel MB, Keck ZY, Foung SKH, Schuster C, Baumert TF.

Front Immunol. 2018 Jun 21;9:1436. doi: 10.3389/fimmu.2018.01436. eCollection 2018. Review.

41.

Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling.

Roca Suarez AA, Baumert TF, Lupberger J.

J Hepatol. 2018 Sep;69(3):564-566. doi: 10.1016/j.jhep.2018.05.033. Epub 2018 Jun 22. No abstract available.

42.

Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.

Keck ML, Wrensch F, Pierce BG, Baumert TF, Foung SKH.

Front Immunol. 2018 May 31;9:1194. doi: 10.3389/fimmu.2018.01194. eCollection 2018. Review.

43.

[Risk of hepatocellular carcinoma after hepatitis C virus cure with direct-acting antivirals: the next challenges].

Hamdane N, Baumert TF, Zeisel MB.

Med Sci (Paris). 2018 May;34(5):391-394. doi: 10.1051/medsci/20183405007. Epub 2018 Jun 13. French. No abstract available.

44.

Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes.

Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, Mailly L, Durand SC, Lucifora J, Durantel D, Pessaux P, Manel N, Hirsch I, Zeisel MB, Pochet N, Schuster C, Baumert TF.

Hepatology. 2018 Nov;68(5):1695-1709. doi: 10.1002/hep.30054. Epub 2018 Jul 10.

45.

Host-targeting therapies for hepatitis C virus infection: current developments and future applications.

Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF.

Therap Adv Gastroenterol. 2018 Mar 21;11:1756284818759483. doi: 10.1177/1756284818759483. eCollection 2018. Review.

46.

Viral manipulation of STAT3: Evade, exploit, and injure.

Roca Suarez AA, Van Renne N, Baumert TF, Lupberger J.

PLoS Pathog. 2018 Mar 15;14(3):e1006839. doi: 10.1371/journal.ppat.1006839. eCollection 2018 Mar. Review.

47.

A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism.

Douam F, Fusil F, Enguehard M, Dib L, Nadalin F, Schwaller L, Hrebikova G, Mancip J, Mailly L, Montserret R, Ding Q, Maisse C, Carlot E, Xu K, Verhoeyen E, Baumert TF, Ploss A, Carbone A, Cosset FL, Lavillette D.

PLoS Pathog. 2018 Mar 5;14(3):e1006908. doi: 10.1371/journal.ppat.1006908. eCollection 2018 Mar.

48.

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.

Riva L, Song OR, Prentoe J, Helle F, L'homme L, Gattolliat CH, Vandeputte A, Fénéant L, Belouzard S, Baumert TF, Asselah T, Bukh J, Brodin P, Cocquerel L, Rouillé Y, Dubuisson J.

J Virol. 2018 Apr 27;92(10). pii: e01982-17. doi: 10.1128/JVI.01982-17. Print 2018 May 15.

49.

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies.

Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T.

Virus Res. 2018 Mar 15;248:53-62. doi: 10.1016/j.virusres.2018.02.016. Epub 2018 Mar 2. Review.

50.

HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.

Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schöneweis K, Seitz S, Tu T, Restuccia A, Frankish J, Dächert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K, Baumert TF, Binder M, Urban S, Bartenschlager R.

Gastroenterology. 2018 May;154(6):1791-1804.e22. doi: 10.1053/j.gastro.2018.01.044. Epub 2018 Feb 1.

Supplemental Content

Loading ...
Support Center